ABSTRACT METABOLIC DISORDERS IN PATIENTS WITH ONCOLOGIC PATHOLOGY

Abstract

Relevance: Metabolic disorders often take on a systemic character. It affects carbohydrate, lipid, and hormonal metabolism. Moreover, these
 changes promote the development and aggravation of several pathologies. The prevalence of metabolic disorders, including obesity, is increasing
 world-wide and in Kazakhstan.
 The study focused on the clinical characteristics of metabolic syndrome (MS) components in pa-tients with cancer comorbidities.
 Methods: The materials included medical records of cancer patients with MS – 35 people (main group) and non-cancerous patients with
 MS – 35 people (control group). MS was diagnosed with a combination of three symptoms: abdominal obesity, high blood pressure, and increased high-density lipoprotein cholesterol (HDL-C) levels. The data were analyzed and processed using the STATIS-TICA 10 software package.
 The significance criterion was p<0.05.
 Results: All studied patients were diagnosed with abdominal obesity. Indicators analysis showed a significant difference in HDL-C concentration in the main and control groups: 3.8 mmol/l in cancer patients and 5.7 mmol/l in the controls. No significant difference in blood pressure was
 found.
 Conclusion: The age of patients with MS evidences a threatening tendency to develop metabolic disorders in young and middle ages. A significantly lower concentration of LDL-C in cancer patients compared with the controls allows using this parameter to predict cancer ]development in
 patients diagnosed with MS. Thus, HDL-C concentration could be used as a metabolic marker for pre-symptomatic diagnostics.